ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data

ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.